Journal of Commercial Biotechnology - IssueJournal of Commercial Biotechnology is the definitive international quarterly publication for bioscience business professionals.
http://www.palgrave-journals.com/jcb/current_issue/
Palgrave Macmillan LtdenJournal of Commercial Biotechnology1462-8732rights@palgrave.comJournal of Commercial Biotechnologyhttp://www.palgrave-journals.com/pal/images/logos_b_o_w/jcb.gif
http://www.palgrave-journals.com/jcb/
Intellectual property and biotechnology innovation: To protect or not protect?
http://feeds.palgrave-journals.com/~r/jcb/rss/current/~3/wOAHXunKMyg/jcb.2009.22
]]>Intellectual property and biotechnology innovation: To protect or not protect?Yali Friedmandoi:10.1057/jcb.2009.22Journal of Commercial Biotechnology 15, 285 (October 2009)Journal of Commercial Biotechnologyhttp://dx.doi.org/10.1057/jcb.2009.22The correlation between medical tourism and biotechnology
http://feeds.palgrave-journals.com/~r/jcb/rss/current/~3/0tCUpJ70YwY/jcb.2009.24
]]>The correlation between medical tourism and biotechnologyDavid G VequistErika Valdezdoi:10.1057/jcb.2009.24Journal of Commercial Biotechnology 15, 287 (October 2009)Journal of Commercial Biotechnologyhttp://dx.doi.org/10.1057/jcb.2009.24The VC manifesto: Special pleading for a damaged cause: Commentary on Simon Witney interview
http://feeds.palgrave-journals.com/~r/jcb/rss/current/~3/-SM2ofEi_Z4/jcb.2009.17
]]>The VC manifesto: Special pleading for a damaged cause: Commentary on Simon Witney interviewWilliam Bainsdoi:10.1057/jcb.2009.17Journal of Commercial Biotechnology 15, 290 (October 2009)Journal of Commercial Biotechnologyhttp://dx.doi.org/10.1057/jcb.2009.17Innovate America: The Technology Innovation Program at NIST
http://feeds.palgrave-journals.com/~r/jcb/rss/current/~3/QCSBdXl30-U/jcb.2009.11
]]>Innovate America: The Technology Innovation Program at NISTAndrew S KleinMrunal S Chapekardoi:10.1057/jcb.2009.11Journal of Commercial Biotechnology 15, 293 (October 2009)April 21, 2009Journal of Commercial BiotechnologyApril 21, 2009http://dx.doi.org/10.1057/jcb.2009.11Valuation of complex license contracts
http://feeds.palgrave-journals.com/~r/jcb/rss/current/~3/esimhV3Oe_c/jcb.2008.43
]]>Valuation of complex license contractsRalph VilligerBoris Bogdandoi:10.1057/jcb.2008.43Journal of Commercial Biotechnology 15, 301 (October 2009)November 4, 2008Journal of Commercial BiotechnologyNovember 4, 2008http://dx.doi.org/10.1057/jcb.2008.43How can pharmaceutical and biotechnology companies maintain a high profitability?
http://feeds.palgrave-journals.com/~r/jcb/rss/current/~3/fMQN99MeSiQ/jcb.2009.3
]]>How can pharmaceutical and biotechnology companies maintain a high profitability?Klaus J NickischJoachim M GreuelKerstin M Bode-Greueldoi:10.1057/jcb.2009.3Journal of Commercial Biotechnology 15, 309 (October 2009)August 11, 2009Journal of Commercial BiotechnologyAugust 11, 2009http://dx.doi.org/10.1057/jcb.2009.3Multiyear patterns regarding the relative availability of venture capital for the US biotechnology industry
http://feeds.palgrave-journals.com/~r/jcb/rss/current/~3/mVEHxCv5fzs/jcb.2009.5
]]>Multiyear patterns regarding the relative availability of venture capital for the US biotechnology industryJ Leslie Glickdoi:10.1057/jcb.2009.5Journal of Commercial Biotechnology 15, 324 (October 2009)March 17, 2009Journal of Commercial BiotechnologyMarch 17, 2009http://dx.doi.org/10.1057/jcb.2009.5Building biotechnology teams: Personality does matter
http://feeds.palgrave-journals.com/~r/jcb/rss/current/~3/gWIM3XUVMZ4/jcb.2009.19
]]>Building biotechnology teams: Personality does matterAnne S YorkKim A McCarthyTodd C Darnolddoi:10.1057/jcb.2009.19Journal of Commercial Biotechnology 15, 335 (October 2009)August 11, 2009Journal of Commercial BiotechnologyAugust 11, 2009http://dx.doi.org/10.1057/jcb.2009.19Beacon Sciences: Commercialisation from biothreat detection to beauty enhancement
http://feeds.palgrave-journals.com/~r/jcb/rss/current/~3/0DfspDX0q1s/jcb.2009.2
]]>Beacon Sciences: Commercialisation from biothreat detection to beauty enhancementRob HanesDamon Borichdoi:10.1057/jcb.2009.2Journal of Commercial Biotechnology 15, 347 (October 2009)April 14, 2009Journal of Commercial BiotechnologyApril 14, 2009http://dx.doi.org/10.1057/jcb.2009.2Legal and Regulatory Update
http://feeds.palgrave-journals.com/~r/jcb/rss/current/~3/7ufYog-6fVI/jcb.2009.23
]]>Legal and Regulatory Updatedoi:10.1057/jcb.2009.23Journal of Commercial Biotechnology 15, 360 (October 2009)August 11, 2009Journal of Commercial BiotechnologyAugust 11, 2009http://dx.doi.org/10.1057/jcb.2009.23Genomics & society: Legal, ethical and social dimensions
http://feeds.palgrave-journals.com/~r/jcb/rss/current/~3/Q1-YPrIRXu0/jcb.2008.53
]]>Genomics & society: Legal, ethical and social dimensionsDr Dominic Clarkdoi:10.1057/jcb.2008.53Journal of Commercial Biotechnology 15, 372 (October 2009)Journal of Commercial Biotechnologyhttp://dx.doi.org/10.1057/jcb.2008.53Commercialization of innovative technologies: Bringing good ideas to the marketplace
http://feeds.palgrave-journals.com/~r/jcb/rss/current/~3/7v2aRcewszk/jcb.2009.18
]]>Commercialization of innovative technologies: Bringing good ideas to the marketplaceArlen D Meyersdoi:10.1057/jcb.2009.18Journal of Commercial Biotechnology 15, 374 (October 2009)Journal of Commercial Biotechnologyhttp://dx.doi.org/10.1057/jcb.2009.18Biotech funding trends: Insights from entrepreneurs and investors
http://feeds.palgrave-journals.com/~r/jcb/rss/current/~3/bq02bIvmkA8/jcb.2009.14
]]>Biotech funding trends: Insights from entrepreneurs and investorsJ Leslie Glickdoi:10.1057/jcb.2009.14Journal of Commercial Biotechnology 15, 376 (October 2009)Journal of Commercial Biotechnologyhttp://dx.doi.org/10.1057/jcb.2009.14